Rodríguez-Fernández, Antonio
Lobo-Prat, Joan
Tarragó, Rafael
Chaverri, Diego
Iglesias, Xavier
Guirao-Cano, Lluis
Font-Llagunes, Josep M.
Funding for this research was provided by:
Agència de Gestió d’Ajuts Universitaris i de Recerca (2020 FI_B1 00195)
Article History
Received: 30 May 2022
Accepted: 2 November 2022
First Online: 9 November 2022
Competing interests
: J.L-P. is an employee and receives salary from ABLE Human Motion S.L. (Barcelona, Spain), which was the sponsor of the present clinical investigation and manufacturer of the ABLE Exoskeleton. J.M.F-L. is co-founder and owns stock in the company ABLE Human Motion S.L. (Barcelona, Spain), which was the sponsor of the present clinical investigation and manufacturer of the ABLE Exoskeleton. The other authors declare no competing interests.